Research on lung cancer detection and treatment. Covers microbial predictors of immunotherapy, MRI detection, microplastics, and RAS-mutant drugs.
Researchers at UT MD Anderson Cancer Center have made significant breakthroughs in cancer treatment, including a promising new therapy for patients with specific EGFR-mutated lung cancer. Additionally, a study published in Science has provided new insights into the cell environment surrounding early breast cancers, shedding light on wh...
The final results of the PECATI trial demonstrate encouraging long-term survival outcomes with the combination of lenvatinib and pembrolizumab in patients with previously treated advanced B3-thymoma and thymic carcinoma. The study found a median progression-free survival of 22.1 months and a median overall survival of 40.2 months.
Researchers develop AI models to identify and classify blood cancers, achieving 99.5% sensitivity and 90.9% positive predictive value. An open-source platform, Turnkey Precision Oncology, helps molecular pathologists interpret genetic sequencing data and generate clinical reports with high accuracy.
A new study published in JNCCN found that comprehensive biomarker testing before treatment for advanced lung cancer was associated with patients living longer. Broad-based genomic sequencing helped identify a wider range of tumor biomarkers, guiding targeted treatment and improving survival outcomes.
Researchers created a single-cell atlas for lung cancer, linking it to clinical data to identify tumor cell types that contribute to metastases and predict interactions between tumor cells and their environment. The study predicts clinical outcomes significantly better than traditional parameters.
Researchers developed a blood-based approach to track small-cell lung cancer and understand its biology. The test uses tiny fragments of material released into the bloodstream to identify molecular patterns characteristic of the disease, allowing doctors to assess its progression and respond to therapy. The study offers a promising rou...
A clinical trial has provided valuable data on how tumor plasticity drives treatment resistance in lung cancer patients. Researchers found that combining osimertinib with platinum and etoposide chemotherapy may not prevent transformation, but rather accelerate it.
Researchers at ICABS 2026 explored personalized cancer vaccines, T-cell therapy, and treatment resistance. Key findings included the development of neoantigen-based vaccines and immune cell metabolism, as well as strategies targeting tumor vulnerabilities.
Alliance Clinical Trials is advancing early detection, improving treatments, and enhancing survivorship for lung cancer patients. The organization is conducting seven active clinical trials focused on prevention, early detection, treatment, and survivorship.
A new study found associations between coagulation-related genes and lung cancer survival, with varying prognostic significance depending on mutation status and tumor location. The research identified four genes, F2, F5, PROS1, and SERPINC1, which may provide additional information for understanding lung cancer prognosis.
A Rutgers-led consortium has been awarded a $6.5 million grant to develop next-generation tools for tobacco control policies, improve lung cancer screening, and strengthen survivorship care. The research aims to provide policymakers with accurate tools to evaluate emerging tobacco products and their impact on population health.
A research team led by Arslan Munir evaluated quantum machine learning approaches for predicting lung cancer using limited symptom and risk-factor data. D-Wave's annealing quantum computers achieved the highest accuracy, reaching 94.31% in simulation and 91.90% on quantum hardware.
A UT San Antonio College of Sciences researcher has developed a novel molecular smart probe that illuminates breast cancer cells during surgery, providing surgeons with cleaner margins and patients lower risk of recurrence. The probe targets proteins in the cells that fuel tumor growth and is paired with an FDA-approved drug to form a ...
Patients with KRAS-mutated lung cancer treated with divarasib lived a median of 18 months and experienced improved disease control compared to standard therapies. Divarasib reduced the risk of cancer progression by 42% and death by 44%, with fewer severe side effects reported.
Researchers at RIKEN have developed a synthetic compound that uses excess carbon monoxide produced by cancer cells to trigger the production of anti-cancer drugs within the cells themselves. The compound selectively targets tumors and avoids harming healthy cells, offering a promising new approach to cancer treatment.
A novel blood test detects lingering lung cancer traces in the bloodstream, predicting relapse risk and guiding timely personalized treatment. The test, known as liquid biopsy, tracks circulating tumor DNA and identifies patients at high risk of recurrence.
Dr. Roy S. Herbst, MD, Ph.D., has been elected to the National Academy of Medicine for his outstanding contributions to lung cancer research and treatment. He is recognized for his work in developing targeted and immune-based therapies, improving patient outcomes, and advancing clinical trial diversity.
The Phase 1b FURTHER trial revealed that firmonertinib achieved durable antitumor activity in patients with EGFR PACC-mutated non-small cell lung cancer, with 43% and 68% objective response rates at 160mg and 240mg daily doses, respectively. Patients with complete clearance of EGFR PACC mutations from their blood experienced higher res...
Researchers have discovered a previously overlooked immune cell that can recognize and kill small cell lung cancer, a form of cancer with limited treatment options. The study found that patients with higher levels of these cells lived longer, uncovering a hidden immune defense that could be exploited to attack these hard-to-treat tumours.
Researchers found a significant association between abdominal fat and lung cancer risk, suggesting that obesity may weaken immune surveillance. Preclinical models also showed that obesity suppresses immune pathways, allowing cancer cells to escape immune detection.
Dr. Elemento's team will develop an AI-human discovery engine to generate hypotheses from human cell and tissue data, test them using robotics testing platforms, and refine the process with human oversight. The goal is to discover new mechanisms that can be targeted pharmacologically and democratize access to AI tools for research.
The American College of Chest Physicians (CHEST) has released a new clinical guideline for tobacco treatment in inpatient settings, synthesizing existing literature to inform key components of inpatient tobacco treatment. The guideline contains six evidence-based recommendations aimed at improving smoking-cessation outcomes and reducin...
MIT researchers have found that lung cancers can use two different mechanisms to evade KRAS-inhibiting drugs, with some tumor cells developing resistance by amplifying the KRAS gene and others changing their tumor type, leading to new insights into treatment resistance and potential targets for new drugs.
A multidisciplinary UCLA research team is developing a noninvasive approach to determine whether indeterminate pulmonary nodules are cancerous. The team aims to improve risk stratification, support earlier and more accurate clinical decision-making, and reduce unnecessary biopsies or surgery.
Extracellular vesicles (EVs) are key players in the pathogenesis of chronic lung diseases, modulating cellular senescence and immune-inflammatory responses. EVs facilitate aberrant intercellular communication, deliver pathogenic miRNAs and proteins, and promote chronic inflammation.
A large Medicare analysis found that depression is associated with higher cancer mortality, while psychotherapy soon after diagnosis reduces cancer risk. Patients with depression had a 21% lower risk of cancer-specific mortality after receiving psychotherapy within four weeks of their diagnosis.
Patients with small cell lung cancer and brain metastases lived 17.4 months with radiosurgery, compared to 8.6 months with whole brain treatment. Radiosurgery was associated with a 40% lower risk of death. The study challenges the long-standing reliance on whole brain treatment for SCLC brain metastases.
Researchers at Ohio State University are testing psilocybin-assisted therapy to reduce depression and emotional distress in patients with advanced lung cancer. The trial aims to determine whether this approach can address the unique psychological challenges faced by lung cancer patients.
The UVA Weber Symposium will discuss the latest research and advancements in metastasis, a complex area of cancer research and care. The event will bring together top scientists and physicians to present findings on cancer metastasis, genetics, and treatment considerations.
A UCLA study found that a dietary supplement, Ca-αKG, reduced lung tumor growth in female mice, but increased tumor growth in male mice. The supplement activated genes associated with better outcomes in women with lung cancer, but had the opposite effect in men.
Researchers at UT MD Anderson Cancer Center have made significant breakthroughs in cancer treatment, developing a targeted antibody that improves outcomes for patients with advanced lung cancer who have faced treatment resistance. The treatment, which combines ivonescimab with chemotherapy, has been shown to extend disease control and ...
Researchers developed an AI model that uses routine chest CT scans to identify patients at risk of pneumonitis, a potentially life-threatening form of lung inflammation. The model, called CIPHER, achieved high predictive power and maintained strong performance despite differences in patient populations and imaging protocols.
The Alliance for Clinical Trials in Oncology is hosting a public webinar highlighting key findings from Alliance and Alliance Foundation Trials studies presented at the 2026 ASCO Annual Meeting. The webinar will feature treatment advances for breast, lung, and prostate cancers, and will include patient representatives to provide insigh...
A rare inherited EGFR mutation is associated with a 25-fold increased risk of lung cancer in non-smokers. Carriers of the mutation are more than 60 times as likely to develop lung cancer as people without it.
The IASLC tumor budding-based grading system identified patients with resected lung squamous cell carcinoma at higher risk of poor outcomes and showed potential to guide selection for adjuvant chemotherapy. High-grade tumors were associated with worse overall and disease-free survival.
A mobile CT unit in Northeast Brazil screened 5,223 individuals, identifying 283 with Lung-RADS 3 or 4, and 19 lung cancers were diagnosed. Community health workers played a crucial role in recruiting 894 participants, mostly from rural areas and with lower educational levels.
A new AI tool has been developed to predict treatment and survival outcomes in patients with advanced non-small cell lung cancer treated with immunotherapy. The tool consistently outperformed standard clinical biomarkers, achieving high accuracy scores in predicting survival outcomes.
A retrospective study found that consolidative stereotactic radiotherapy improves intracranial control and survival outcomes for patients with EGFR-mutant NSCLC and limited brain metastases. Patients without an intracranial complete response to osimertinib may derive the greatest overall survival benefit from SRT.
The PAPILLON trial demonstrates durable clinical benefit and longest median overall survival reported to date for people with lung cancer carrying an EGFR exon 20 insertion mutation. Amivantamab plus chemotherapy extended overall survival by a clinically meaningful 6 months and cut disease progression risk by 60%.
Patients with class II and class III BRAF alterations in non-small cell lung cancer (NSCLC) have distinct clinicopathologic and genomic characteristics. Class III alterations are associated with worse prognosis and shorter overall survival. STK11, KEAP1, and SMARCA4 co-mutations also linked to worse outcomes.
A Phase 3 trial showed gotistobart significantly improved overall survival, with a 43% reduced risk of death, compared to docetaxel. Higher exposure to gotistobart was associated with improved survival, supporting the selected dosing regimen.
A randomized trial found that brain MRI surveillance alone preserves cognitive function without a difference in survival, supporting MRI surveillance as the standard of care for patients with small cell lung cancer. No apparent difference was observed in overall survival and progression-free survival between the groups.
The eight-year ADAURA update reports a significant overall survival benefit with adjuvant osimertinib in patients with completely resected, EGFR-mutated stage IB-IIIA NSCLC. The study found an eight-year overall survival rate of 74% with osimertinib versus 58% with placebo.
The REZILIENT 3 trial found a six-month improvement in median progression-free survival with the combination of zipalertinib and platinum-pemetrexed chemotherapy. The study showed a 50% reduction in disease progression or death and a substantially higher response rate compared to chemotherapy alone.
The PAPILLON study demonstrates the longest overall survival for patients with EGFR exon 20 insertion-positive advanced NSCLC using first-line amivantamab-chemotherapy. The study found a median overall survival of 34.3 months with amivantamab-chemotherapy versus 27.9 months with chemotherapy.
The Phase 3 DESTINY-Lung04 trial showed that trastuzumab deruxtecan significantly improves progression-free survival in patients with HER2-mutant non-small cell lung cancer, with a median PFS of 14.3 months compared to 8.3 months with pembrolizumab plus chemotherapy. T-DXd also demonstrated a higher objective response rate and better d...
The ARROS-1 trial revealed a 94% objective response rate and 94% nine-month duration-of-response rate among TKI-naive patients with advanced ROS1-positive NSCLC. Intracranial activity was also notable, with a 100% intracranial objective response rate and 78% 12-month intracranial duration-of-response rate.
The investigational combination of pumitamig and elfetabart drozuntecan demonstrated encouraging early antitumor activity in patients with small cell lung cancer, with a 70.4% overall response rate. The combination also showed a manageable safety profile, supporting further clinical development.
The MAVERICK trial found that MRI surveillance alone significantly improved cognitive failure-free survival by 40% compared to MRI plus PCI in patients with limited-stage and extensive-stage small-cell lung cancer. Serious treatment-related adverse events were also less frequent with MRI surveillance alone.
The Phase III ARTEMIS-008 trial shows that risvutatug rezetecan significantly improves overall survival in patients with relapsed small-cell lung cancer. The treatment reduced the risk of death by 54% and improved progression-free survival and response rates compared to topotecan.
A Phase 1 study showed the investigational therapy demonstrated a manageable safety profile, with 33.3% of patients achieving objective response at the recommended 2.5mg/kg dose. The treatment was well-tolerated, with no treatment-related deaths and only one patient discontinuing due to an adverse event.
The Phase 3 IMpower030 trial found that perioperative atezolizumab plus chemotherapy doubled event-free survival to 62.8 months compared to 34.9 months for chemotherapy alone. The study also showed higher pathological response rates with the atezolizumab regimen.
The phase III TAISHAN-302 trial found Tam-Peli to significantly improve overall survival, progression-free survival, and objective response rate in patients with relapsed small-cell lung cancer compared to topotecan. The study also showed a favorable safety profile for Tam-Peli.
A phase 3 trial shows ivonescimab significantly improves overall survival compared to pembrolizumab in patients with PD-L1-positive advanced NSCLC. The median overall survival was 30.8 months with ivonescimab versus 22.6 months with pembrolizumab.
Results from the DeLLphi-309 study suggest that extended-interval dosing regimens of tarlatamab may offer patients greater treatment flexibility while maintaining comparable clinical activity. The study found improved overall survival rates with less frequent dosing schedules, but with similar treatment-emergent adverse event rates.
A Phase III trial found that local consolidative therapy after dual immunotherapy did not improve overall or progression-free survival in patients with metastatic NSCLC. The study tested whether reducing residual tumor burden with radiation or surgery after dual immunotherapy could improve systemic disease control.
The EVOKE-03/KEYNOTE-D46 trial found a numerically longer progression-free survival and higher response rates with sacituzumab govitecan plus pembrolizumab, but no statistically significant benefit in PFS or OS for patients with PD-L1-high metastatic NSCLC
The phase 1b DeLLphi-308 study found that subcutaneous tarlatamab achieved serum exposures comparable to the approved intravenous dosing while maintaining a favorable safety profile, with 30% preliminary objective response rate in patients with ES-SCLC.
A new case report describes a 68-year-old woman with stage IV lung adenocarcinoma who developed severe hemolysis after receiving pembrolizumab, despite a negative Coombs test. The patient's hemoglobin declined from 11-12 g/dL to 6.4 g/dL, and laboratory markers of hemolysis improved with corticosteroid treatment. The case highlights th...
A new class of protein-based MRI contrast agent detects invasive lung cancer and metastatic disease at earlier stages than conventional imaging approaches. The technology targets collagen type I, a structural protein found at elevated levels in aggressive lung tumors and metastatic lesions.